Biosimilar Breakdown: Can Lower Drug Prices Survive the PBM Squeeze?

Featured Guest: Stan Mehr — Editor of Biosimilars Review & Report, healthcare journalist, and market strategist with decades of expertise in biosimilars, pharma reform, and drug pricing dynamics. https://biosimilarsrr.com/about/

In this critical episode, we explore the evolving biosimilars landscape, pricing transparency, and the tangled web of pharmacy benefit managers (PBMs) with biosimilars expert Stan Mehr. From inflated rebates to private-label manipulation, Stan sheds light on how PBMs and policy changes under the Inflation Reduction Act are reshaping access to lower-cost drugs.

If you're an employer, payer, or pharma manufacturer navigating the biosimilar space, this episode is your roadmap to understanding where opportunity lives—and where it's quietly being suffocated.

Key Topics Covered:

• The $25B+ in biosimilar savings… and why it could vanish
• Why employers aren’t seeing those savings—and how PBMs control the game
• The problem with private-label biosimilars 
• How the Inflation Reduction Act could unintentionally collapse biosimilar pipelines
• What fiduciary responsibility means for employer health plans
• Long-term predictions: who survives, who exits, and who profits

Michael's LinkedIn

Randy's LinkedIn

Sponsored by:
Peek: A game-changing prescription shopping solution that allows its members to view all their prescription cost options across cash discount programs and their insurance in one easy-to-use platform. Peek is currently being offered to organizations to help both employees and plan sponsors save money on their prescription spend. https://peekmeds.com/.

Institute for Integrated Health (IIH): Health care benefits, insurance coverage regulations, and doing business in the healthcare industry can be complicated. At IIH, Dr. Randy Vogenberg and his team understand these unique challenges and provides strategic guidance customized to every client. To help overcome your unique challenges, IIH delivers education, planning and advisory on market trends, and U.S. health care market intelligence. The firm’s decades of proven success are due to strategic collaboration with associates from the business, clinical, and scientific communities. https://iih-online.com/.